LAG3 and B-cell chronic lymphocytic leukemia: Murine models of chronic lymphocytic leukemia (CLL) treated with both anti-PD-1 and anti-LAG3 displayed a significantly lower number of CLL cells in the spleen, along with a decrease in Tregs and an increase in Teffs (Wierz et al., 2018).